Login to Your Account

Vertebral Fractures Cut by 68 Percent

Amgen's Denosumab Meets High Expectations in FREEDOM Study

By Jennifer Boggs

Wednesday, September 17, 2008
The much-anticipated data from Amgen Inc.'s pivotal fracture study of denosumab in postmenopausal women demonstrated a significant reduction in vertebral fracture rate and relatively clean safety profile, ending a month and a half of speculation among investors since top-line data were released in late July. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription